The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations

Research output: Contribution to journalReview articlepeer-review

Abstract

Therapeutic advances in the treatment of lung cancer are in part due to a more complete understanding of its genomic portrait. The serial monitoring of tumor genotypes, which are instable and prone to changes under selective pressure, is becoming increasingly needed. Although tumor biopsies remain the reference standard for the diagnosis and genotyping of lung cancer, they are invasive and not always feasible. The “liquid biopsies” have the potential to overcome many of these hurdles, allowing a rapid and accurate identification of de novo and resistant genetic alterations and a real-time monitoring of treatment responses. In this review, we provide insights into new liquid diagnostic platforms and discuss the role of circulating tumor cells and circulating tumor DNA in the diagnosis and identification of resistance mutations in lung cancer.

Original languageEnglish
Article number1
JournalCurrent Oncology Reports
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 1 2017
Externally publishedYes

Keywords

  • Circulating tumor cell
  • Circulating tumor DNA
  • Disease monitoring
  • Early detection
  • Intra-tumor heterogeneity
  • Liquid biopsy
  • Molecular resistance

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The Emerging Role of “Liquid Biopsies,” Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations'. Together they form a unique fingerprint.

Cite this